Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals — Investor Presentation (January 2020)

35 slides from Deciphera Pharmaceuticals's investor presentation, Jan 13, 2020

  1. Slide 1: Defeating Cancer: The Challenge. Our Mission.

    DEFEATING CANCER: The Challenge. Our Mission. January 2020 Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Deciphera Pharmaceuticals, Inc. for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by Deciphera Pharmaceuticals, Inc. or any

  3. Slide 3: Executing on Our Mission

    Executing on Our Mission At Deciphera, we are focused on discovering, developing, and bringing important new medicines to patients for the treatment of cancer. Ripretinib: Positive results from INVICTUS Phase 3 study in ≥4th line GIST Ripretinib: NDA submitted and preparing for potential U.S. launch

  4. Slide 4: Robust Clinical Stage Oncology Pipeline of Novel Kinase Inhibitors

    PRECLINICAL PHASE 1 PHASE 1B/2 PHASE 3 REGULATORY SUBMISSION COMMERCIAL RIGHTS GIST ≥4th Line (INVICTUS Study) GIST 2nd Line (INTRIGUE Study) Systemic Mastocytosis and Other Solid Tumors Tenosynovial Giant Cell Tumor Other Solid Tumors Solid Tumors in Combination with Paclitaxel (includes breast, ov

  5. Slide 5: 2020 Expected Milestones for the Year Ahead

    Potential FDA approval and commercial launch in advanced GIST Submit EU marketing authorization application to EMA Complete enrollment in the INTRIGUE Phase 3 study in 2nd line GIST Present Phase 1 study expansion data Select Phase 2 dose for tenosynovial giant cell tumor (TGCT) and open expansion c

  6. Slide 6: Ripretinib: Potential to Change Practice in Advanced GIST

    Ripretinib: Potential to Change Practice in Advanced GIST Novel TKI designed to inhibit broad range of mutations in KIT and PDGFRα Notes: TKI=tyrosine kinase inhibitor. Strong efficacy and safety data from randomized Phase 3 INVICTUS study NDA submitted to FDA for advanced GIST Marketing application

  7. Slide 7: Ripretinib: A Novel Kinase Switch Control Inhibitor

    Ripretinib: A Novel Kinase Switch Control Inhibitor z A unique dual mechanism of action that regulates the kinase switch pocket and activation loop Prevents the activation loop from binding to the switch pocket Locks the kinase in the inactive (“off”) state Notes: ATP=adenosine triphosphate. Switche

  8. Slide 8: Ripretinib: Designed to Address a Broad Range of Mutations in GIST

    Ripretinib: Designed to Address a Broad Range of Mutations in GIST KIT Mutations Drive ~80% of GIST Ripretinib: Broad Mutational Coverage in KIT and PDGFRα Source: Hemming M et al. Translational insights into gastrointestinal stromal tumors and current clinical advances. Annals of Oncology; 29: 2037

  9. Slide 9: Significant Unmet Medical Need Post-Imatinib

    Significant Unmet Medical Need Post-Imatinib Estimated Incidence of GIST: U.S. 4,000-6,000(1) 1st Line Treatment: Imatinib* mPFS: 18.9 months(2) mOS: 46.8 months(3) 1L 2L 2nd Line Treatment: Sunitinib* mPFS: 5.6 months(4) mOS: 17.0 months(4) ~2,000 U.S. incident patients eligible for treatment(6) No

  10. Slide 10: Global Pivotal Phase 3 Study in ≥4th Line GIST

    Global Pivotal Phase 3 Study in ≥4th Line GIST 10 3+ Prior Lines of Therapy(1) Notes: QD=daily; (1) Phase 3 pivotal study in patients with ≥4th line GIST who previously received at least imatinib, sunitinib, and regorafenib; (2) Following progression: (a) placebo patients can crossover to ripretinib

  11. Slide 11: Progression-Free Survival (PFS) Benefit

    Progression-Free Survival (PFS) Benefit Notes: Data presented at European Society for Medical Oncology (ESMO) Congress 2019; (1) Double-blind period. Reduction in Risk of Disease Progression or Death Versus Placebo 85% 100 80 60 40 20 0 0 2 4 6 8 10 12 14 Months Survival probability (%) Ripretinib 1

  12. Slide 12: Durable Response with Ripretinib

    Durable Response with Ripretinib Patients Who Responded (n=8) ORR 9.4% n=8 ORR 0% n=0 Ripretinib n=85 Placebo n=44 P=0.0504 Median duration of response has not been reached yet Notes: Data presented at ESMO Congress 2019; ORR=Objective response rate; ORR was not statistically significant. Confirmed

  13. Slide 13: Overall Survival (OS) Benefit

    Overall Survival (OS) Benefit Notes: Data presented at ESMO Congress 2019; Data includes all time periods, including dose escalations. Placebo arm includes patients taking placebo who, following progression, were crossed-over to ripretinib treatment; (1) Due to hierarchical testing procedures of the

  14. Slide 14: Ripretinib Was Generally Well Tolerated

    Ripretinib Was Generally Well Tolerated RIPRETINIB PLACEBO Preferred Term Any Grade (n=85) Grade 3/4 (n=85)(1) Any Grade (n=43)(2) Grade 3/4 (n=43) (1),(2) Any TEAE or grade 3/4 TEAE(3) 84 (99%) 42 (49%) 42 (98%) 19 (44%) Alopecia 44 (52%) 0 2 (5%) 0 Fatigue 36 (42%) 3 (4%) 10 (23%) 1 (2%) Nausea 33

  15. Slide 15: Ripretinib: A Potential Best-In-Class Treatment for Advanced GIST

    Ripretinib: A Potential Best-In-Class Treatment for Advanced GIST 15 Ripretinib was associated with a favorable safety profile Ripretinib showed a clinically meaningful improvement in overall survival vs. placebo, reducing the risk of death by 64% (median OS of 15.1 months vs. 6.6 months; HR=0.36, 9

  16. Slide 16: Ripretinib: Phase 1 GIST Cohorts Positive Updated Results

    Line of Therapy(1) 2nd Line (n=31) 3rd Line (n=28) ≥4th Line (n=83) Median Progression Free Survival 46 weeks 36 weeks 24 weeks Objective Response Rate (confirmed responses only) 19% 14% 7% Median Duration of Response 80 weeks NE 76 weeks Mean Treatment Duration(2) 56 weeks 58 weeks 45 weeks 16 Note

  17. Slide 17: Ongoing Global Pivotal Phase 3 Study in 2nd Line GIST

    106 Active Sites(1) 18 Countries Ongoing Global Pivotal Phase 3 Study in 2nd Line GIST 17 Notes: (1) Number of open sites current as of January 3, 2020; (2) Phase 3 pivotal study in 2nd line patients who previously received imatinib. Prior Imatinib Therapy(2) 1:1 Randomization Open-label n=358 Ripre

  18. Slide 18: Ripretinib: Rapid Clinical Development, 4 Years from IND to NDA Submission

    2020 2019 2015-2017 2018 Nov 2015 First Patient Dosed in Phase 1 Dose Escalation Feb 2018 First Patient Dosed in INVICTUS Phase 3 Study in 4th Line GIST Nov 2018 Full Enrollment in INVICTUS Feb 2019 First Patient Dosed in INTRIGUE Phase 3 Study in 2nd Line GIST Aug 2019 Top-line INVICTUS Data Releas

  19. Slide 19: Commercial Preparations are on Track for Potential 2020 Launch

    Commercial Preparations are on Track for Potential 2020 Launch MARKET ACCESS Market access leadership in place Market access field team recruiting on track Distribution and patient support/assistance strategies defined and build on track SALES VP of sales in place Customer segmentation & targeting c

  20. Slide 20: GIST Treatment Occurs in Both Academic and Community Institutions

    GIST Treatment Occurs in Both Academic (~30%) and Community (~70%) Institutions; Many Leading Institutions Have Participated in Ripretinib Trials Academic Community Ripretinib Trial Site Largest Institutions By GIST Patient Volume Notes: Deciphera internal analysis of claims data, 2019.

  21. Slide 21: Market Research Verbatims

    Market Research Verbatims In Deciphera Market Research, Oncologists Highlight Key Areas of Unmet Need Notes: Deciphera internal market research, 2019. Commonly Cited Unmet Needs “We have a very effective front-line treatment available... which is very rewarding.” Need for more effective and tolerabl

  22. Slide 22: Market Research Shows Importance of OS, PFS, and Tolerability in GIST

    Deciphera Market Research Shows the Importance of OS, PFS, and Tolerability in GIST and High Interest in Ripretinib Product Profile 2nd Line 4th Line OS (61%) PFS (61%) Safety / Tolerability (51%) ORR (45%) Duration of response (42%) Quality of life (37%) DCR / CBR (37%) NCCN Guidelines (37%) Qualit

  23. Slide 23: Deciphera's Vision for Ripretinib in GIST

    Leverage ripretinib’s differentiated mechanism of action and currently known clinical profile to address unmet medical needs Deciphera’s Vision for Ripretinib in GIST is to be the Standard of Care Across All Approved Indications Fast-to-market strategy designed to fulfill urgent unmet need in 4th li

  24. Slide 24: DCC-3014: A Highly Selective and Potent CSF1R Inhibitor

    Summary DCC-3014: A Highly Selective and Potent CSF1R Inhibitor Phase 1 dose escalation study ongoing Generally well tolerated at doses of up to 50 mg in patients receiving three-day loading, followed by 20 mg QD maintenance regimen Initial proof-of-concept in three patients with diffuse-type tenosy

  25. Slide 25: Unmet Medical Need in Tenosynovial Giant Cell Tumor (TGCT)

    Unmet Medical Need in Tenosynovial Giant Cell Tumor (TGCT) Rare, locally aggressive tumors Genetic translocation causes overproduction of CSF-1, triggering migration of inflammatory cells to tumor sites Symptoms Surgical resection is standard treatment High rate of recurrence in diffuse TGCT CSF1R i

  26. Slide 26: DCC-3014: Preliminary Phase 1 Data in Initial TGCT Patients

    DCC-3014: Preliminary Phase 1 Data in Initial TGCT Patients Notes: Data presented at CTOS Annual Meeting 2019; dashed lines denote 30% decrease and 20% increase in tumor size threshold for partial response and progressive disease, respectively, per RECIST version 1.1; C=cycle; D=day; RECIST=response

  27. Slide 27: DCC-3014: TGCT Case Studies from the Phase 1 Study

    DCC-3014: TGCT Case Studies from the Phase 1 Patient 1 Patient 2 Notes: Data presented at CTOS Annual Meeting 2019. Baseline C3D1 C10D1 48% 84% Baseline C3D1 25% 24-year-old female patient diagnosed with diffuse-type TGCT (right posterior knee) in June 2016, three prior surgeries, and recurrence/pro

  28. Slide 28: Rebastinib: A Highly Potent and Selective TIE2 Inhibitor

    Rebastinib: A Highly Potent and Selective TIE2 Inhibitor Development status Two ongoing studies in combination with paclitaxel or carboplatin Encouraging preliminary results from Part 1 of the Phase 1b/2 study in combination with paclitaxel presented in October 2019 Selected Phase 2 dose and activat

  29. Slide 29: Rebastinib: Phase 1b/2 Study in Combination with Paclitaxel

    Rebastinib: Phase 1b/2 Study in Combination with Paclitaxel Notes: (1) 80 mg/m2 60 minute IV infusion. Rebastinib 50 mg BID + Paclitaxel(1) Rebastinib 100 mg BID + Paclitaxel(1) n = 19 n = 24 Cohort 1 Triple Negative Breast Cancer Cohort 2 Inflammatory Breast Cancer Cohort 3 Ovarian Cancer Cohort 4

  30. Slide 30: Rebastinib: Encouraging Preliminary Anti-tumor Activity with Paclitaxel

    Rebastinib: Part 1 of Phase 1b/2 Study in Combination with Paclitaxel Shows Encouraging Preliminary Anti-tumor Activity Time on Treatment and Best Response for Rebastinib 50 mg BID + Paclitaxel(1) Time on Treatment and Best Response for Rebastinib 100 mg BID + Paclitaxel(1) Notes: Data presented at

  31. Slide 31: Rebastinib: Combination with Paclitaxel Was Generally Well Tolerated

    Rebastinib: Part 1 Data of the Phase 1b/2 Study Showed the Combination with Paclitaxel Was Generally Well Tolerated 50 mg BID (n=24) 100 mg BID (n= 19) Total (n=43) Preferred Term Any grade Grade ≥ 3 Any grade Grade ≥ 3 Any grade Grade ≥ 3 Fatigue 8 (33%) 1 (4%) 5 (26%) 0 13 (30%) 1 (2%) Constipatio

  32. Slide 32: DCC-3116 is a Potent & Selective ULK Inhibitor Designed to Inhibit Autophagy

    DCC-3116 is a Potent & Selective ULK Inhibitor Designed to Inhibit Autophagy First-in-class opportunity for new therapeutic in RAS mutant cancers RAS mutant cancers have high basal levels of autophagy DCC-3116 observed preclinically to durably and potently inhibit autophagy in RAS mutant cancer cell

  33. Slide 33: Financial Highlights

    As of September 30, 2019 Financial Highlights 51 MM (basic) 58 MM (fully-diluted) $635 MM Cash Expected to Fund Operating Expenses and CapEx into 2022 Shares Outstanding Cash, Cash Equivalents & Marketable Securities

  34. Slide 34: Significant Expected 2020 Milestones Across the Pipeline

    Significant Expected 2020 Milestones Across the Pipeline Ripretinib Potential FDA approval and commercial launch in advanced GIST Submit EU marketing authorization application to EMA (2H20) Complete enrollment in the INTRIGUE Phase 3 study in 2nd line GIST (2H20) Present Phase 1 study expansion data

  35. Slide 35: Thank You

    THANK YOU

Deciphera Pharmaceuticals — Investor Presentation (January 2020) on 6ix